Review Article
Hepatitis C and Kidney Transplantation
Table 4
Clinical trials of monotherapy with conventional IFN or pegylated IFN in hemodialysis patients with chronic hepatitis C.
| | Period | Patients number | Antiviral Agent | Doses of IFN or Peg-IFN | SVR |
| | Degos et al. [132] | 2001 | 37 | IFN α | 3 MU three times weekly | 19% | | Mukherjee et al. [152] | 2003 | 9 | Peg-IFN-α2b | 1 mcg/kg/week | 22% | | Ozdemir et al. [133] | 2004 | 20 | IFN α | 3–6 MU three times weekly | 40% | | Rivera et al. [134] | 2005 | 27 | IFN α ()
Peg-IFN-α2a () | 3 MU three times weekly
135 mcg/week | 40% | | Mahmoud et al. [61] | 2005 | 18 | IFN α | 3 MU three times weekly | 44% | | Grgurevic et al. [135] | 2006 | 15 | IFN α | MU/week ()
MU/week for 3 months, then MU/week for another 3 months () | 40% | | Rocha et al. [136] | 2006 | 46 | IFN α | 3 MU three times weekly | 22% | | Sporea et al. [153] | 2006 | 10 | Peg-IFN-α2a | 180 mcg/week | 30% | | Russo et al. [151] | 2006 | 16 | Peg-IFN-α2b | 1 mcg/kg/week (), 0.5 mcg/kg/week () | 12.5% | | Covic et al. [154] | 2006 | 78 | Peg-IFN-α2a | 135 mcg/week | 14% | | Espinosa et al. [36] | 2007 | 16 | Peg-IFN-α2a ()
Peg-IFN-α2b () | 1.5 mcg/week (),
135 mcg/kg/week () | 25% | | Casanovas-Taltavull et al. [155] | 2007 | 12 | Peg-IFN-α2a | 135 mcg/week | 25% | | Ucmak et al. [156] | 2008 | 12 | Peg-IFN-α2a | 135 mcg/week | 50% | | Sikole et al. [157] | 2008 | 14 | Peg-IFN-α2a | 135 mcg/week | 41% | | Liu et al. [158] | 2008 | 25 | Peg-IFN-α2a | 135 mcg/week | 48% | | Ayaz et al. [159] | 2008 | 22 | Peg-IFN-α2a | 135 mcg/week | 50% | | Akhan et al. [160] | 2008 | 12 | Peg-IFN-α2a | 135 mcg/week | 50% | | Werner et al. [168] | 2010 | 22 | Peg-IFN-α2a ()
Peg-IFN-α2b () | 180 mcg/week
1.5 mcg/kg/week 1 mcg/kg/week (1 patient) | 45% |
|
|
IFN: interferon; MU: million units; Peg-IFN: pegylated interferon; SVR: sustained virological response.
|
